Posted by Michael Wonder on 08 May 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for tardive dyskinesia, including recently approved Ingrezza
8 May 2017 - Report expected to review evidence on deutetrabenazine (Austedo), tetrabenazine (Xenazine), and valbenazine (Ingrezza); scoping document will be open for public comment until 26 May.
The ICER has posted a draft scoping document for an upcoming report assessing the comparative clinical effectiveness and value of drugs for treatment of tardive dyskinesia, a condition characterised by involuntary body movements often associated with long-term use of certain antipsychotic medications.
ICER's report is expected to review evidence on three drug treatments. Valbenazine (Ingrezza, Neurocrine Biosciences), was recently approved by the FDA as the first drug with a specific indication for tardive dyskinesia; deutetrabenazine (Austedo, Teva Pharmaceuticals) is approved for use in Huntington's disease and is currently under review for a tardive dyskinesia indication, while tetrabenazine (Xenazine, Lundbeck) is approved for use in Huntington's disease and is often used in tardive dyskinesia, though it is not formally indicated for such use.
The draft scoping document will be open to public comment for three weeks until 26 May 2017.
